GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets

GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic.